Haploidentical Hematopoietic Stem Cell Transplantation With Early ATG and Low Dose Post-transplant Cyclophosphamide

Condition(s) studied

Investigational drug(s) / intervention(s)

ATG-LDPTCy: antithymocyte globulin with low dose post-transplant cyclophosphamide

Study summary

Aim of this study is to investigate the effect of early administration of anti-thymocyte globulin and post-transplant low-dose cyclophosphamide in heploidentical hematopoietic stem cell transplantation.

Eligibility

Primary outcome measure(s)

• Emgraftment Rate — From the date of transplantation until 28 days after transplantation
  cumulative incidence of donor-dominant engraftment by day 28 (by case)
• Time to Engraftment — From the date of transplantation until first neutrophil count over 500/uL for 3 consecutive tays
  median time to neutrophil engraftment
• Acute Graft-Versus-Host Disease — From the date of transplantation until 365 days after transplantation
  Incidence of acute GVHD ≥ grade 2
• Chronic Graft-Versus-Host Disease — From the date of transplantation until the date of documentation of highest level of chronic GVHD, assessed up to 2 years after transplantation
  Incidence of moderate to severe chronic GVHD

Trial sites (1)

More Samsung Medical Center trials in South Korea